Cardiac complications in cancer treatment - A review.
作者： Xianchi Li , Min Liu , Rongrong Sun , Yi Zeng , Shuang Chen
DOI: 10.1016/J.HJC.2016.12.003
关键词:
摘要: Cardiac dysfunction is often associated with effective cancer treatment. A number of targeted therapies against have been observed to cause cardiac dysfunction. In some instances, a patient may outlive his or her but die due heart failure. Recent research has focused on the development new avenues and technological advancements monitor clinical cardiotoxicity anticancer These newer treatment options are also increasingly more post-cancer life. The present review article expands current view complications involved in along recent developments area.
core.ac.uk
sci-hub.se 参考文章(28)
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). Ecancermedicalscience. ,vol. 8, pp. 433- 433 ,(2014) , 10.3332/ECANCER.2014.433
J.D. Cohen, J.E. Babiarz, R.M. Abrams, L. Guo, S. Kameoka, E. Chiao, J. Taunton, K.L. Kolaja, Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations Toxicology and Applied Pharmacology. ,vol. 257, pp. 74- 83 ,(2011) , 10.1016/J.TAAP.2011.08.020
Iván P Uray, John H Connelly, Vilmos Thomázy, Gregory L Shipley, William K Vaughn, O.Howard Frazier, Heinrich Taegtmeyer, Peter J.A Davies, Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. Journal of Heart and Lung Transplantation. ,vol. 21, pp. 771- 782 ,(2002) , 10.1016/S1053-2498(02)00390-X
Douglas B. Sawyer, Christian Zuppinger, Thomas A. Miller, Hans M. Eppenberger, Thomas M. Suter, Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1β and Anti-erbB2 Potential Mechanism for Trastuzumab-Induced Cardiotoxicity Circulation. ,vol. 105, pp. 1551- 1554 ,(2002) , 10.1161/01.CIR.0000013839.41224.1C
Hesham Mohamed Korashy, Hani A Al-Suwayeh, Zaid H Maayah, Mushtaq Ahmad Ansari, Sheikh Fayaz Ahmad, Saleh A Bakheet, None, Mitogen-Activated Protein Kinases Pathways Mediate the Sunitinib-Induced Hypertrophy in Rat Cardiomyocyte H9c2 Cells Cardiovascular Toxicology. ,vol. 15, pp. 41- 51 ,(2015) , 10.1007/S12012-014-9266-Y
Brian B. Hasinoff, Daywin Patel, Kimberley A. O'Hara, Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib Molecular Pharmacology. ,vol. 74, pp. 1722- 1728 ,(2008) , 10.1124/MOL.108.050104
Yuqin Zhao, Tao Xue, Xiaochun Yang, Hong Zhu, Xiaofei Ding, Liming Lou, Wei Lu, Bo Yang, Qiaojun He, Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells Toxicology and Applied Pharmacology. ,vol. 248, pp. 20- 27 ,(2010) , 10.1016/J.TAAP.2010.07.007
R Kumar, M-C Crouthamel, D H Rominger, R R Gontarek, P J Tummino, R A Levin, A G King, Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. British Journal of Cancer. ,vol. 101, pp. 1717- 1723 ,(2009) , 10.1038/SJ.BJC.6605366
Annamaria Rapisarda, Giovanni Melillo, Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia Nature Reviews Clinical Oncology. ,vol. 9, pp. 378- 390 ,(2012) , 10.1038/NRCLINONC.2012.64
Edwin P. Rock, Vicki Goodman, Janet X. Jiang, Kooros Mahjoob, S. Leigh Verbois, David Morse, Ramzi Dagher, Robert Justice, Richard Pazdur, Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma Oncologist. ,vol. 12, pp. 107- 113 ,(2007) , 10.1634/THEONCOLOGIST.12-1-107